Welcome to our dedicated page for First Wave BioPharma news (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma stock.
First Wave BioPharma, Inc. (NASDAQ: FWBI), now operating as Entero Therapeutics, Inc., generates news primarily as a clinical-stage biopharmaceutical company focused on targeted, non-systemic therapies for gastrointestinal (GI) diseases. Company press releases describe a pipeline that has included biologic and small-molecule candidates such as adrulipase, latiglutenase, capeserod, and niclosamide for a range of GI indications.
News coverage for FWBI has highlighted multiple themes. One recurring category involves capital markets and financing transactions, including registered direct offerings and private placements of common stock and warrants, with stated uses of proceeds for working capital and general corporate purposes. These updates often reference shelf registration statements on Form S-3 and the role of placement agents.
Another important news stream relates to clinical and scientific developments. Releases have discussed Phase 2 clinical trial data for latiglutenase in celiac disease, invited papers in peer-reviewed journals, and abstracts accepted for presentation at major conferences such as Digestive Disease Week. These communications describe work on quantitative mucosal scales and serologic diagnostics in celiac disease, as well as the potential role of latiglutenase as an oral biotherapeutic.
Corporate and strategic news items have included the completion of a business combination with ImmunogenX, Inc., bringing latiglutenase into the GI-focused pipeline, and participation in investor and healthcare conferences where management presents the company’s development strategy and anticipated milestones.
Investors following FWBI-related news can use this page to review historical announcements about GI pipeline evolution, scientific publications, financing activities, and corporate transactions associated with the company that transitioned to Entero Therapeutics, Inc.
First Wave BioPharma (FWBI) issued a Letter to Shareholders regarding its upcoming Annual Meeting on December 17, 2021. CEO James Sapirstein highlighted the company’s transformation, including the acquisition of First Wave Bio and the expansion of its clinical pipeline from one to two assets and five programs. 2021 saw a capital raise of approximately $48 million, with promising Phase 2 clinical trials underway, particularly for niclosamide therapies targeting gastrointestinal diseases. The company aims to advance its clinical programs and enhance shareholder value in 2022.
First Wave BioPharma announced the appointment of Dr. Brian Feagan to its scientific advisory board, aimed at enhancing clinical development of niclosamide for treating inflammatory bowel diseases (IBDs). Dr. Feagan, an expert in IBD, joins a team of established professionals to guide the company’s pipeline programs centered around niclosamide and adrulipase. This move is anticipated to bolster First Wave's Phase 2 trials for ulcerative proctitis and COVID-19-related GI infections, expanding its therapeutic reach in gastrointestinal disorders.
First Wave BioPharma (NASDAQ:FWBI) announced that James Sapirstein, the company’s Chairman and CEO, will participate in a panel at the 2021 BioFlorida Conference on December 10, 2021. The panel, titled “Fueling Florida's Life Sciences,” aims to explore trends in Florida's biosciences industry. The event will feature notable industry leaders discussing the growth and future of biopharmaceuticals in Florida. First Wave BioPharma is advancing therapies for gastrointestinal diseases, including COVID-19 related conditions and ulcerative diseases.
First Wave BioPharma (NASDAQ:FWBI) has completed a review of safety data from the first 25 patients in Part 2 of its RESERVOIR Phase 2 trial for FW-COV, a treatment for COVID-19-related gastrointestinal infections. An independent data monitoring committee recommended continuing enrollment, noting no safety issues. The trial aims to evaluate the efficacy of niclosamide in clearing SARS-CoV-2 from the GI tract, with topline results expected next year. This treatment could be crucial given the rise of the Omicron variant, with 43% of COVID patients potentially affected by GI symptoms.
First Wave BioPharma (NASDAQ:FWBI) announced a restructuring of its payment terms with former shareholders of First Wave Bio, Inc. to extend payments into 2023. The company had made an upfront payment of $3 million and issued $4 million in stock, with a remaining $15 million to be paid in smaller installments instead of larger lump sums originally scheduled for late 2021 and early 2022. Immediate payment of $2 million was triggered upon the dosing of the first patient in the FW-UP Phase 2 trial for ulcerative proctitis, enhancing liquidity for ongoing clinical trials.
First Wave BioPharma (NASDAQ:FWBI) has announced the formation of a steering committee for its PASSPORT Phase 2a clinical trial, which investigates the effectiveness of FW-ICI-AC in treating Grade 1 and 2 colitis and diarrhea in oncology patients on immune checkpoint inhibitors (ICIs). Notable experts from leading cancer centers will guide the study, which aims to enroll 60 patients to assess the safety and preliminary efficacy of the niclosamide-based treatment. The trial's primary focus is on patient safety and the potential to enable continued immunotherapy for cancer patients.
On October 19, 2021, First Wave BioPharma (NASDAQ:FWBI) received FDA clearance for its Phase 2a PASSPORT trial to investigate FW-ICI-AC, a treatment for Grade 1 and 2 colitis and diarrhea in oncology patients on immune checkpoint inhibitors. This double-blind, placebo-controlled study will enroll 60 patients to evaluate safety, tolerability, and preliminary efficacy. The trial aims to address diarrhea affecting up to 30% of cancer patients, which can jeopardize their treatment. The approved IND protocol promises accelerated patient enrollment and efficient trial completion.
First Wave BioPharma has initiated a Phase 2b clinical trial for its topical formulation of niclosamide (FW-UP) targeting ulcerative proctitis and ulcerative proctosigmoiditis. This trial follows favorable results from Phase 1b, where niclosamide exhibited a clinical remission rate of 59%, outperforming the steroid budesonide's 38-44%. With over 825,000 ulcerative colitis cases in the U.S. annually, the market potential is approximately $5 billion. The trial will include up to 28 participants across clinical sites in Italy, Austria, and Germany.
First Wave BioPharma has announced the expansion of its Scientific Advisory Board (SAB) to enhance the development of its clinical programs, particularly in gastrointestinal diseases and COVID-19-related gastrointestinal infections. The new members include Dr. Anthony Opipari and Dr. Richard Marlink, who bring extensive expertise in their respective fields. The company aims to leverage the unique backgrounds of these experts to advance its pipeline, including therapies based on niclosamide and adrulipase. This strategic move could potentially boost the company's clinical development and innovation.
First Wave BioPharma (FWBI) has initiated a Phase 2b clinical trial for its topical formulation, FW-UP, targeting ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS). This trial follows promising preliminary results from a previous Phase 1a/2a trial, where the low-dose FW-UP demonstrated a clinical remission rate of 59%. The Phase 2b trial will enroll up to 28 patients, comparing FW-UP with placebo, administered as enemas. The trial aims to evaluate the efficacy of higher doses of niclosamide, a key component believed to possess substantial anti-inflammatory properties, against standard treatments.